title: Characterization of oral disintegrating film containing donepezil for Alzheimer disease.
abstract: The aim of this study was to develop a taste-masked oral disintegrating film (ODF) containing donepezil, with fast disintegration time and suitable mechanical strength, for the treatment of Alzheimer's disease. Hydroxypropyl methylcellulose, corn starch, polyethylene glycol, lactose monohydrate and crosspovidone served as the hydrophilic polymeric bases of the ODF. The uniformity, in vitro disintegration time, drug release and the folding endurance of the ODF were examined. The in vitro results showed that 80% of donepezil hydrochloride was released within 5 minutes with mean disintegration time of 44 seconds. The result of the film flexibility test showed that the number of folding time to crack the film was 40 times, an indication of sufficient mechanical property for patient use. A single-dose, fasting, four-period, eight-treatment, double-blind study involving 16 healthy adult volunteers was performed to evaluate the in situ disintegration time and palatability of ODF. Five parameters, namely taste, aftertaste, mouthfeel, ease of handling and acceptance were evaluated. The mean in situ disintegration time of ODF was 49 seconds. ODF containing 7 mg of sucralose were more superior than saccharin and aspartame in terms of taste, aftertaste, mouthfeel and acceptance. Furthermore, the ODF was stable for at least 6 months when stored at 40°C and 75% relative humidity.
authors.affiliation: Department of Pharmaceutical Technology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia.
authors.forename: Kai Bin
authors.initials: KB
authors.lastname: Liew
authors.forename: Yvonne Tze Fung
authors.initials: YT
authors.lastname: Tan
authors.forename: Kok Khiang
authors.initials: KK
authors.lastname: Peh
mesh_terms: D000284:Administration, Oral; D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D000077265:Donepezil; D004311:Double-Blind Method; D004337:Drug Carriers / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000378:metabolism*; D008297:Male; D010880:Piperidines / Q000008:administration & dosage / Q000378:metabolism*; D012995:Solubility / Q000187:drug effects; D013549:Sweetening Agents / Q000008:administration & dosage / Q000378:metabolism*; D013649:Taste / Q000187:drug effects / Q000502:physiology*; D013718:Tensile Strength; D055815:Young Adult
chemical_list: D004337:Drug Carriers; D007189:Indans; D010880:Piperidines; D013549:Sweetening Agents; D000077265:Donepezil